BEAM-201

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The purpose of this study is to determine the safety and effectiveness of an experimental form of therapy, known as BEAM-201. BEAM-201 uses immune cells, called T cells, that are genetically changed to identify cancer cells. In this study, T cells are collected from a healthy human donor and have been modified in a laboratory. If the genetically changed T cells recognize and attach to cancer cells, they may have the ability to kill those cancer cells. The U.S. Food and Drug Administration (FDA) allows BEAM-201 to be used in research.

Patients with T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma (L-LL), where the disease has come back (relapsed) or has not responded to treatment (refractory) may be eligible for the study.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at leibfreidb [at] chop.edu or 267-242-5953.

Eligibility & Criteria

IRB #:
22-020678
Official Title:
A PHASE 1/2, DOSE-EXPLORATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY AND EFFICACY OF MULTIPLEX BASE EDITED, ALLOGENEIC ANTI-CD7 CAR-T CELLS (BEAM-201) IN RELAPSED/REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR T-CELL LYMPHOBLASTIC LYMPHOMA (T-LL)
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 Months - 30 Years
Gender:
All
Study Categories:

Visit Criteria

As a participant in the research, you will:

  • Receive the study drug BEAM-201.
  • Avoid taking certain medications (steroids, chemotherapy agents).
  • Stay in the hospital for at least 10 days after receiving the study drug.
  • Complete follow up visits.
  • Have research blood samples drawn.
Leader
David T. Teachey

David Teachey, MD